Last reviewed · How we verify
IPI-145
IPI-145 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms that suppresses B-cell and T-cell signaling to reduce malignant cell proliferation and survival.
IPI-145 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms that suppresses B-cell and T-cell signaling to reduce malignant cell proliferation and survival. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | IPI-145 |
|---|---|
| Also known as | Duvelisib, Copiktra, PI3K Inhibitor |
| Sponsor | SecuraBio |
| Drug class | PI3K delta/gamma inhibitor |
| Target | PI3K delta (PI3Kδ), PI3K gamma (PI3Kγ) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IPI-145 selectively inhibits PI3Kδ and PI3Kγ, which are predominantly expressed in hematopoietic cells. By blocking these kinases, the drug disrupts critical survival and proliferation signals in B-cell and T-cell malignancies, leading to apoptosis and reduced tumor burden. This dual selectivity aims to minimize toxicity compared to pan-PI3K inhibitors while maintaining efficacy in lymphoid cancers.
Approved indications
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Diarrhea
- Neutropenia
- Transaminitis
- Fatigue
- Infections
Key clinical trials
- Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome (PHASE1)
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS (PHASE1, PHASE2)
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL (PHASE1, PHASE2)
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype (PHASE3)
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (PHASE2)
- Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy (PHASE1)
- Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |